Is a post-approval change a prior approval supplement, a CBE-30, a CBE-0 or an annual report change?

1Decision table: 33 common CMC changes and their category.

Most rows are FDA examples that hold only under the conditions stated, so read the cited section before filing. “2004” is FDA’s Changes to an Approved NDA or ANDA, “2014” its guidance on changes to document in annual reports, “2001” its questions and answers on the 2004 guidance’s first version, “Addendum” its SUPAC equipment addendum, and SUPAC-IR its 1995 guidance for immediate-release tablets and capsules. Paragraphs are of 21 CFR 314.70, which also governs ANDAs through 314.97.¹²³⁴⁵⁶

Behind every row is one test: whether the potential for an adverse effect on identity, strength, quality, purity or potency is substantial, moderate or minimal. Labelling changes have their own lists in 314.70.¹ This page covers US rules only; for the EU, see Type IA, IB and II variations.

2How to place a change the table doesn’t list.

1. Check it is a change. FDA must be told of each change “beyond the variations already provided for” in the application; editorial changes are excluded.¹²
2. Read the regulation, then the guidance, newest first. Paragraphs (b)(2), (c)(2), (c)(6) and (d)(2) of 314.70 name changes in each category.¹ Then the 2014 list; the 2004 guidance overrides earlier categories, except for components and composition, where SUPAC still applies.³²
3. Take the lighter route. 314.70(a)(3) requires you to use any regulation or guidance that allows a less burdensome notification.¹ The 2014 list is only a recommendation: a holder whose risk evaluation points higher may file a supplement.³
4. Check what the assessment found. A change that has adversely affected the product, such as one forming a new degradant, goes in a prior approval supplement whatever its usual category.²
5. Group related changes. A site move that brings equipment and process changes is filed in the most restrictive of their categories.²

2.1Judgement calls the sources settle.

• Scale beyond ten times. SUPAC-IR put a batch over 10 times the biobatch in a “Changes being effected supplement”.⁶ FDA’s 2001 answers, still listed in its August 2026 draft, moved it: “All changes in the scale of the nonprotein drug product manufacturing batches can be reported in an annual report”, unless other changes come with it. Beyond ten times, FDA wants SUPAC-IR’s Level 2 data.⁴⁷
• Same design and operating principle. FDA’s equipment addendum sorts each unit operation’s equipment “by class (operating principle) and subclass (design characteristic)”: wet high-shear granulators are vertical or horizontal by impeller position. A move between them can be assessed by a risk-based approach with a rationale, kept on file with the data for FDA to review.⁵ Same class and subclass is the annual-report case; a different design is a CBE-30 unless listed elsewhere.²³ A different class, such as tray to fluid bed drying, can be a change of technology needing prior approval.²

3What “30 days” means, and how long FDA takes.

• Day 30 counts from FDA’s receipt. Distribution “may begin not less than 30 days after receipt of the supplement by FDA”: one received on Monday 2 February 2026 allows distribution from 4 March. It waits if FDA says within those days that prior approval is needed or information is missing, and a later disapproval can stop it.¹ FDA itself says a substantive review within 30 days is “unlikely”.⁴
• Priority and expedited review. You can ask for expedited review for public health reasons, such as a drug shortage, or extraordinary hardship, such as after a fire.¹² An ANDA priority supplement is one eligible under CDER’s MAPP 5240.3; its 8-month goal needs pre-submission facility correspondence. GDUFA sets no goals for CBE supplements or annual reports.¹⁰
• Annual report timing. Within 60 days of the anniversary of US approval, covering the year that ends on that date.¹

4When FDA disagrees with your category.

FDA checks the category before it reviews the change, and what follows depends on the application:

• ANDAs. FDA quality staff told an April 2023 generic drug forum that a CBE downgraded to the annual report is withdrawn at FDA’s request, and a CBE elevated to prior approval gets a notification letter, after which the applicant resubmits it as a prior approval supplement. Common reasons for elevation were drug substance process, drug product site, container closure and stability protocol changes, and an added sterile filling line.¹¹
• NDAs and BLAs. For a move to a facility not in an acceptable state of CGMP compliance, where a CBE-30 is filed instead of a prior approval supplement, “FDA may convert the submission to a PAS absent any action by the applicant”; an ANDA applicant is told to resubmit.¹²
• Annual reports. “If the submitted change is inappropriate for documentation in an annual report, the applicant will be notified of the correct category and additional information may be requested.”³

FDA’s advice to generic applicants:¹¹

“Do not rely on data to justify classification, but instead justify reporting category based on cited guidance applicable sections and nature of proposed change(s).” Managing Quality Post-Approval Supplements, FDA, SBIA Generic Drug Forum, April 2023¹¹

4.1What preapproval inspectors check.

FDA’s preapproval inspection programme, implemented on 10 August 2026, names 314.70 and 314.97 as the change reporting rules and tells investigators to “Verify that the firm’s change management system assesses the need for new or revised ECs (e.g., to respond to observed variability)”, with procedures to set “appropriate reporting categories for new or revised ECs where needed”. Its example: an applicant proposes blender revolutions as an established condition with an annual-report category; if inspectors find change management deficient, they record it on Form FDA 483, and FDA asks the applicant to update the application “to reflect a higher reporting category”.¹³ Have recent change controls ready with the category each chose and the guidance section behind it.

5Example: one change control, four filings.

This example is invented. Orlavine 25 mg immediate-release tablets were approved under an ANDA on 14 May 2019 from a 40 kg biobatch and are made in 120 kg batches. Change control CC-26-052, approved on 12 January 2026, bundles four changes.

The four share a change control but not a cause, so each takes its own category: the 2004 guidance’s most-restrictive rule covers only related changes, such as the granulator and the larger batch it brings.²

The new batch is 480 ÷ 40 = 12 times the biobatch, so the 2001 answers call for SUPAC-IR’s Level 2 data, carried by validation batches 26-016 to 26-018: updated batch records, three months’ accelerated stability on 26-016, 26-017 on long-term stability, and Case B dissolution profiles at 15, 30, 45, 60 and 120 minutes against pre-change batches.⁴⁶ Batch 26-019 shipped once those results were in, because the effects must be assessed first.¹

Neither 314.70 nor the 2014 guidance defines when a change is implemented. 314.70(a)(2) separates making a change from distributing product made with it, so this record dates it from the first batch and notes first distribution beside it.¹³ Both dates fall in the year that ended on 14 May 2026, so both annual-report changes go in the report due by 13 July 2026.¹

5.1The annual report entry.

5.2What a supplement must contain.

“Only the applicant may submit a supplement to an application.”¹ A CDMO that makes a change tells the holder under the quality agreement, which FDA says should settle “the types of changes to report to each other and to FDA”.¹⁴

6BLAs and biosimilars: the same tiers under 601.12.

21 CFR 601.12 uses the same three levels of potential and four routes, and adds responsible personnel. Its prior approval examples include a new master cell bank or seed, a new virus removal method and a change of source material or cell line.¹⁵ Which guidance classifies the change depends on the product:

• Most 351(a) biologics. FDA’s June 2021 guidance covers vaccines, plasma-derived products, cell and gene therapies and others, but excludes biosimilars, blood components and the specified products of 601.2(a), such as monoclonal antibodies for in vivo use and therapeutic recombinant DNA-derived products.¹⁶¹⁷
• Specified products, biosimilars included. FDA’s July 1997 guidance for specified biotechnology and synthetic biological products, and its December 2021 annual-report guidance. FDA’s final questions and answers of October 2026 count biosimilars and interchangeables as specified products and send them to those two, with ICH Q12 as a framework and the June 2021 guidance where applicable.¹⁸

7Comparability protocols, ICH Q12 and what is current.

A comparability protocol, ICH Q12’s post-approval change management protocol, sets out the studies and acceptance criteria for a specified change in advance and is filed in the original application or in a prior approval supplement.¹¹² Once approved, a prior approval change typically drops to a CBE-30 or CBE-0, and a CBE change to the annual report. If the studies are not done or the criteria are not met, “any reduced reporting category is not justified” and the change goes by its normal route. Site changes that need a preapproval inspection may not qualify.¹² ICH Q12’s established conditions are the legally binding elements of the application, so any change to them needs a submission;¹⁹ FDA’s guidance on using them in US applications is still a May 2021 draft.²⁰

Nothing newer replaces this guidance: FDA’s June 2026 ANDA postapproval guidance still points to the 2004 guidance, and its August 2026 container closure draft lists the 2004 and 2014 guidances, the 2001 answers, the 2021 biologics guidances and ICH Q12 as relevant.²¹⁷ The PDUFA VII and GDUFA III goals run to September 2027.⁸⁹

8How it runs in Seal.

In Seal, a post-approval CMC change keeps one technical change and its evidence connected to a separate assessment for each market: the approved state, the established conditions it touches, the reporting route and any protocol. Each product, market and site gets its own signed implementation gate, so batches made under a change still awaiting US approval cannot ship to the US because another market has approved it. If the work goes beyond an approved protocol, Seal opens a new assessment instead of applying the lower category. Change control links each change to those market assessments and keeps pending filings beside it, because internal approval is not market permission.

Regulatory submissions records each supplement or annual report from content plan to outcome, with the commitments it creates and their owners, due dates and required evidence. Neil can prepare a commitment evidence review, mapping each commitment to what proves it and flagging where a closed task is not proof; your regulatory and quality owners decide what is sent.